The Solution Provider for 
Drug Discovery in Oncology

ProQinase is a leading preclinical service company dedicated to support pharmaceutical and biotech clients in the development of novel therapies for cancer treatment. The company has a long-standing scientific experience in the fields of protein kinase and tumor angiogenesis research.

Currently 239 in-house produced catalytically active protein kinases and 10 kinase substrates are offered for sale and more than 358 protein kinases are available for biochemical kinase assay services (HTS, selectivity profiling and IC50 determination).

Hits derived from biochemical kinase assays can be further characterized at ProQinase in cellular phosphorylation assays and in various functional cellular assays (migration assay, soft agar assay, angiogenesis assay).

For further evaluation of lead compounds ProQinase offers various in vivo testing services including subcutaneous (xenograft) models, orthotopic tumor models with in vivo and ex vivo bioluminescence analysis and a unique angiogenesis assay.

In addition, ProQinase provides custom-tailored solutions as support for cancer drug discovery projects.